Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results from the study that showed that avanafil was effective in as early as 15 minutes after dosing when analyzed both by subject and attempt.  Of the subjects attempting intercourse </=15 minutes of dosing, 83% had successful intercourse.  Additionally, eighty percent (80%) of all study-wide sexual attempts made within 15 minutes of dosing were successful.

The study entitled, "An Open-label, Long-term Evaluation of the Safety and Efficacy of Avanafil in Men with Erectile Dysfunction" was presented during the Late Breaking Trials Session on November 12, 2011.  Dr. McCullough concluded that based on the results of the study, this onset of action suggests that avanafil, if approved, is potentially well-suited for on-demand treatment in men with mild to severe ED.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation.  VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUSVIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in c
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique business ... adjusting, tweaking and testing virtual models and 3D test ... , “I enjoyed being involved as a judge,” stated ... showed a commendable range exploring the technical capabilities of ... and the creativity of the contestants.” , Array Architects ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 ... Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, ... regulatory positions at the director level and above from ... struggling to stay on top of rapid breakthroughs in ... result, many diagnostic companies have been forced to fold, ...
(Date:9/30/2014)... release is available in German . ... around several quantum dots in a semiconductor layer. Quantum dots ... of atomic processes. If a short laser pulse is fired ... the quantum dot experiences a change in the electromagnetic field ... the emission of light by the dot. As soon as ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... significance of this past Sunday? , ,Yes, it was Mother's ... Day ("Victory in Europe"), but it was also the 106th ... of the world's greatest economists. These days, while Hayek is ... seminal work "The Road to Serfdom," he was also a ...
...
... a $75,000 grant to make the financial relationships and ... , ,The grant came from the Joyce Foundation , ... , ,All the information is already available, but not always ... with keeping track of the financial relationships of state officials, ...
Cached Biology Technology:Midwest cities in fight over municipal broadband access 2Midwest cities in fight over municipal broadband access 3Midwest cities in fight over municipal broadband access 4Ethics Board to put financial disclosures online with new grant 2
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
(Date:9/30/2014)... farm runoff in Hawaii is causing tumors in endangered ... study, published Tuesday in the peer-reviewed open-access journal ... up in algae that the turtles eat, promoting the ... internal organs. , Scientists at Duke University, the University ... (NOAA) conducted the study to better understand the causes ...
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... announced today the launch of its newest journal, ... in January 2012. Cell Reports , the first open-access ... the entire life science spectrum. The journal will focus on ... articles. As with all Cell Press journals, the primary criterion ...
... 1, 2011 /PRNewswire-Asia/ -- Clearbridge Accelerator announced today that ... well-established venture capitalist based in the Silicon Valley. Mr ... of Draper Fisher Jurvetson (DFJ), is well known for ... Clearbridge Accelerator is a technology incubator ...
... of the International Osteoporosis Foundation (IOF) has issued ... the efficacy and safety of two minimally invasive ... (VP) and balloon kyphoplasty (BKP). The review also ... future studies and highlights research questions still unresolved. ...
Cached Biology News:Announcing Cell Reports -- a new open-access journal from Cell Press 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 3Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 4Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 6IOF urges systematic osteoporosis management after vertebral fracture augmentation 2
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
Biology Products: